Stevens-Johnson syndrome associated with topical nitrogen mustard therapy.
Newman
J M
JM
Department of Dermatology, Cleveland Clinic Foundation, OH 44195-5032, USA.
Rindler
J M
JM
Bergfeld
W F
WF
Brydon
J K
JK
D000279:Administration, Cutaneous; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005938:Glucocorticoids; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects*; D009182:Mycosis Fungoides / Q000188:drug therapy; D009364:Neoplasm Recurrence, Local; D009824:Ointments; D011701:PUVA Therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D005938:Glucocorticoids; D009824:Ointments; D005446:Fluocinolone Acetonide; D008466:Mechlorethamine; C035394:fluocinolone